Financial Statement Release of Atria Plc, 1 January – 31 December 2025

Atria reported record full-year net sales of EUR 1,813.7m (up EUR 58.4m y/y) and adjusted EBIT of EUR 69.9m (3.9% of sales, up from 3.7%), with Q4 net sales EUR 476.5m and adjusted EBIT EUR 14.0m. Reported EBIT of EUR 64.0m includes a EUR 5.9m non‑recurring cash expense for disposal/restoration of the Kuopio site; free cash flow was EUR 69.8m and adjusted ROE (rolling 12m) 11.0%. The Board proposes a higher dividend of EUR 0.75/share (0.69 prior) and expects adjusted EBIT to increase in 2026, while flagging risks from African swine fever in Estonia, labour strikes and volatile pork markets; management also announced EUR~122m+ of strategic production and energy investments and published a TOGETHER 2030 strategy.

Analysis

Market structure: Atria’s results and heavy capex (EUR82.4m convenience-factory; EUR23m Sweden; EUR16m Kauhajoki) position it as a consolidation/scale winner in Northern European packaged meat and convenience foods. Near-term supply shocks (ASF in Estonia, avian influenza in Sweden) tighten regional protein supply and increase pricing power for vertically integrated players; Atria’s improved poultry efficiency and China chicken exports are immediate competitive advantages. Cross-asset: higher protein prices support commodity-linked names and may increase short-term input-cost volatility; EUR-denominated balance sheet limits FX shock but SEK exposure from Sweden operations suggests monitoring SEK moves >5%.

Risk assessment: Tail risks include renewed ASF/avian influenza outbreaks, a larger-than-expected Finnish labour strike recurrence, or China import restrictions—any of which could cut 2026 EBIT by a material mid-single-digit million amount; worst-case (widespread ASF + export ban) could erase >EUR30m of EBIT. Timewise: expect immediate market reaction in days to ASF/avian-flu headlines, quarterly confirmation in 6–12 weeks, and structural payoff from capex in 12–24 months (energy savings >EUR5m/yr; Kauhajoki savings ~EUR3m/yr). Hidden dependencies: execution risk on the Nurmo EUR82m project and dependency on subsidies (EUR24.7m); delays would defer margin uplift and cash payback.

Trade implications: Direct play is long Atria (Helsinki-listed) into 2026 guidance — upside from operational leverage as capex converts to lower energy and higher throughput. Use asymmetric option structures (9–15 month call spreads or long-dated calls financed by selling lower-delta calls) to capture upside while capping theta. Pair trades: long Atria vs short HKScan (peer execution risk) 1:1 to isolate strategy/epidemiological risk. Rotate into European packaged-foods/consumer staples vs commodity-exposed processors; reduce exposure to pure pork processors in Baltic region.

Contrarian angles: Consensus over-weights the ASF downside; market is underpricing Atria’s structural capex-driven margin improvement (target: >3.9% adj EBIT margin trending toward 5% within 24 months if projects hit). Watch for mispricing after any ASF headline-driven sell-off: disciplined buy-on-weakness threshold at -5% intraday and add more below -12% for a tactical accumulator. Possible unintended consequence: faster-than-expected poultry price inflation could attract new entrants or trigger retail pushback, compressing gross margins if Atria cannot pass through fully.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Atria (Helsinki-listed, Atria Plc) within 30 days to capture 2026 upside from guidance and capex-driven efficiency; add on any ASF/AI-driven pullback >5% and size up to 4–5% if shares fall >12% intraday.
• Implement an options collar: buy 12–15 month calls (target delta ~0.35) financed by selling 12–15 month calls (delta ~0.15) to cap cost—objective multiple 2x payoff if adjusted EBIT rises >10% year-on-year; if implied vol <30%, prefer straight long-dated calls instead.
• Pair trade: go long Atria and short HKScan (Helsinki peer) 1:1 sized notional for 3–9 months to exploit execution and export exposure divergence; tighten if HKScan releases positive restructure news or Atria delays Nurmo project beyond Q4 2026.
• Hedge operational tail-risk: buy 3-month puts (or set cash stop) if new ASF/avian influenza cases >2 farms in Estonia/Sweden within a 30-day window OR if Finnish labour action resumes with nationwide overtime bans; reduce Atria exposure by 50% on those triggers.